RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of “Hold” by Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned a consensus recommendation of “Hold” from the thirteen brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $9.56.

A number of research firms recently commented on RAPT. Piper Sandler cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Stifel Nicolaus reissued a “hold” rating and set a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Wells Fargo & Company decreased their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Finally, HC Wainwright raised shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Thursday, December 26th.

RAPT Therapeutics Stock Performance

Shares of RAPT opened at $1.32 on Friday. The company has a 50 day moving average price of $1.43 and a 200-day moving average price of $2.05. RAPT Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $27.35. The stock has a market capitalization of $46.14 million, a PE ratio of -0.48 and a beta of 0.07.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.09. Equities research analysts forecast that RAPT Therapeutics will post -2.86 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in RAPT. Bank of New York Mellon Corp increased its stake in shares of RAPT Therapeutics by 24.0% in the second quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock worth $349,000 after acquiring an additional 22,175 shares during the period. Los Angeles Capital Management LLC increased its stake in shares of RAPT Therapeutics by 66.2% in the second quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock worth $258,000 after acquiring an additional 33,692 shares during the period. Acadian Asset Management LLC increased its stake in shares of RAPT Therapeutics by 4,183.3% in the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock worth $1,424,000 after acquiring an additional 456,275 shares during the period. Federated Hermes Inc. increased its stake in shares of RAPT Therapeutics by 188.7% in the second quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock worth $2,428,000 after acquiring an additional 520,368 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of RAPT Therapeutics by 108.1% in the second quarter. Renaissance Technologies LLC now owns 203,900 shares of the company’s stock worth $622,000 after acquiring an additional 105,900 shares during the period. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.